GlassScriptPhysician profile
Kheni A Brasso
NPI 1205398617
$2,996.90
in general payments reported to CMS, 2019-2025
23 companies · $469 in 2025
The $469 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $810 · 2022: $339 · 2023: $761 · 2024: $619 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,847.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $445.21 | 2022-2023 | Krystexxa, Tepezza |
| Daiichi Sankyo INC. | $431.15 | 2021-2023 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $285.91 | 2021-2025 | Saphnelo |
| Eisai INC. | $234.40 | 2025 | |
| Tg Therapeutics, INC. | $229.44 | 2024-2025 | |
| Glaxosmithkline, LLC. | $217.25 | 2021 | |
| Amgen INC. | $150.56 | 2024 | Krystexxa, Tepezza |
| Lundbeck LLC | $142.92 | 2022-2023 | Vyepti |
| Janssen Biotech, INC. | $125.36 | 2022-2024 | Stelara, Tremfya |
| Argenx US, INC. | $124.92 | 2024 | Vyvgart Hytrulo |
| Biogen, INC. | $111.63 | 2021-2024 | Tysabri |
| Alexion Pharmaceuticals, INC. | $110.39 | 2023 | Ultomiris |
| Csl Behring | $102.93 | 2021 | |
| Pfizer INC. | $90.95 | 2021-2024 | |
| Grifols USA, LLC | $37.34 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $26.34 | 2021 | |
| Mylan Specialty L.P. | $25.91 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $25.57 | 2021 | |
| Pharmacosmos Therapeutics INC. | $17.89 | 2021 | |
| Biocryst US Sales Co., LLC | $17.49 | 2021 | |
| Viiv Healthcare Company | $16.95 | 2022 | |
| Genentech USA, INC. | $13.72 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kheni Brasso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.